Combination therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of liver cancer called hepatocellular carcinoma (HCC) that is advanced (spread or cannot be removed by surgery).
- You have already tried a checkpoint inhibitor (a type of immunotherapy) and it did not work or your cancer got worse.
- Your liver is still working fairly well (Child-Pugh score 7 or less) and you have not had liver problems like confusion from liver disease.
- You have not had a liver transplant, do not have cancer spread to your brain, and do not have a build-up of fluid in your belly or chest that needs draining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new combination of drugs for people with advanced liver cancer who have not had prior treatment. It compares the study drug QL1706 plus standard treatments to see if it can help shrink tumors or slow the disease.
This study tests whether combining a standard treatment for liver cancer (TACE) with three additional medications can help people whose cancer cannot be cured. The goal is to see if the combination is more effective than TACE alone.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.